The global hepatology market size accounted for USD 16.31 billion in 2024, grew to USD 18.26 billion in 2025 and is projected to surpass around USD 50.40 billion by 2034, representing a healthy CAGR of 11.94% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hepatology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hepatology Market, by Treatment Type, 2024-2034
8.1.1. Antiviral Drugs
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Immunosuppressants
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Targeted Therapy
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Chemotherapy
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Corticosteroids
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Immunoglobulins
8.1.7.1. Market Revenue and Forecast (2021-2034)
9.1. Hepatology Market, by Disease Type, 2024-2034
9.1.1. Hepatitis
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Liver Cancer
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Genetic Disorders
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Autoimmune Diseases
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Non- Alcoholic Fatty Liver Diseases
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.1.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Disease Type (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1. Astellas Pharma Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Merck & Co. Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Laboratories
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bristol- Myers Squibb
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. AbbVie Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Emergent BioSolutions Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. F. Hoffmann- La Roche AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eli Lilly and Company
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Viatris Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Gilead Sciences, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample